Evaluating CyberKnife for treating prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness and side effects of CyberKnife stereotactic ablative body radiation (SABR) in patients with prostate cancer. The CyberKnife system uses advanced technology to deliver high doses of radiation precisely to the tumor while minimizing damage to surrounding healthy tissue. The study aims to determine if this treatment can improve patient outcomes and assess its impact on quality of life over time. Patients with low to intermediate risk prostate cancer will be monitored for their response to this innovative treatment approach.

Why it matters

Who can join: the full rules

Inclusion

* Histologically proven prostate adenocarcinoma
* Biopsy within 12 months of date of registration required except for patients who already meet criteria for enrollment in the high risk arm of the protocol. For these patients, repeat biopsy will be at the discretion of the treating physician. In general, repeat biopsy is recommended for these patients, but is not required if it will not affect the treating physician's management decisions in regards to the care of the patient.
* Clinical Stage I-IV, MX-M0 (AJCC VERSION 9)
* M-stage determined by physical exam, CT, MRI, bone scan, PSMA PET/CT, or biopsy.
* Prostate volume: ≤ 100 cc (recommended not required)
* Determined using: volume = π/6 x length x height x width
* Measurement from CT, MRI or ultrasound ≤ 90 days prior to registration.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* No prior prostatectomy or cryotherapy of the prostate
* No prior radiotherapy to the prostate or lower pelvis
* No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.
* Completion of patient questionnaires in section 3.7.
* Consent signed

Exclusion

* No prior prostatectomy or cryotherapy of the prostate
* No prior radiotherapy to the prostate or lower pelvis
* No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.

Where it's running

• Orange Coast Memorial Medical Center
  Fountain Valley, California, United States Recruiting
• Saddleback Memorial Medical Center
  Laguna Hills, California, United States Recruiting
• Long Beach Memorial Medical Center
  Long Beach, California, United States Recruiting

Study contacts

• Principal investigator: Asif Harsolia, MD — MemorialCare
• Study coordinator: Shelbe Tolentino (Santos)
• Email: stolentino2@memorialcare.org
• Phone: 562-933-9068

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.